Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

(2016) P. G. Richardson et al.   BLOOD

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results

(2016) S. J. Harrison et al.   CLINICAL CANCER RESEARCH

Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma

(2016) Xuemei Cai et al.   JOURNAL OF CLINICAL ONCOLOGY

Proteasome inhibitors

(2015) Beverly A. Teicher et al.   BIOCHEMICAL PHARMACOLOGY

Phase 1, multicenter, open-label, dose-escalation, combination study (NCT02103335) of pomalidomide (POM), marizomib (MRZ, NPI-0052), and dexamethasone (DEX) in patients with relapsed and refractory multiple myeloma (MM); study NPI-0052-107 preliminary results

(2015) A. Spencer et al.   Clinical Lymphoma Myeloma & Leukemia

Molecular basis of resistance to proteasome inhibitors in hematological malignancies

(2015) Denise Niewerth et al.   DRUG RESISTANCE UPDATES

Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914

(2015) Eva M. Huber et al.   STRUCTURE

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

(2015) S Atrash et al.   Blood Cancer Journal

Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System

(2014) Q. Dou et al.   CURRENT CANCER DRUG TARGETS

Utilization of Translational Bioinformatics to Identify Novel Biomarkers of Bortezomib Resistance in Multiple Myeloma

(2014) Deanna J. Fall et al.   Journal of Cancer

Carfilzomib-related acute kidney injury may be prevented by N-acetyl-l-cysteine

(2014) Rimda Wanchoo et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors

(2013) D. Niewerth et al.   HAEMATOLOGICA

Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib

(2013) Tamer B. Shabaneh et al.   PLoS One

Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials

(2013) Robert Z. Orlowski   SEMINARS IN ONCOLOGY

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

(2012) M. Alsina et al.   CLINICAL CANCER RESEARCH

Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance

(2012) Andrew J. Kale et al.   JOURNAL OF MEDICINAL CHEMISTRY

Specific Cell-Permeable Inhibitor of Proteasome Trypsin-like Sites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib

(2011) Anne C. Mirabella et al.   CHEMISTRY & BIOLOGY

Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

(2011) B. C. Potts et al.   CURRENT CANCER DRUG TARGETS

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

(2011) Michael Millward et al.   INVESTIGATIONAL NEW DRUGS

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells

(2011) N E Franke et al.   LEUKEMIA

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model

(2010) Ajita V. Singh et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

(2010) Donna E. Reece et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

(2009) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells

(2009) T Rückrich et al.   LEUKEMIA

Discovery and development of the anticancer agent salinosporamide A (NPI-0052)

(2008) William Fenical et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

(2008) P. Moreau et al.   HAEMATOLOGICA